tbuckley/cabot-search huggingface dataset:
Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage
Authors: Jamie Soul, Sara L Dunn, Sanjay Anand, Ferdinand Serracino-Inglott, Jean-Marc Schwartz, Ray P Boot-Handford, Tim E Hardingham
Journal: Annals of the Rheumatic Diseases (2017)

Introduction Osteoarthritis (OA) is a heterogeneous and complex disease. We have used a network biology approach based on genome-wide analysis of gene expression in OA knee cartilage to seek evidence for pathogenic mechanisms that may distinguish different patient subgroups. Methods Results from RNA-Sequencing (RNA-Seq) were collected from intact knee cartilage at total knee replacement from 44 patients with OA, from 16 additional patients with OA and 10 control patients with non-OA. Results were analysed to identify patient subsets and compare major active pathways. Results The RNA-Seq results showed 2692 differentially expressed genes between OA and non-OA. Analysis by unsupervised clustering identified two distinct OA groups: Group A with 24 patients (55%) and Group B with 18 patients (41%). A 10 gene subgroup classifier was validated by RT-qPCR in 16 further patients with OA. Pathway analysis showed increased protein expression in both groups. PhenomeExpress analysis revealed group differences in complement activation, innate immune responses and altered Wnt and TGFβ signalling, but no activation of inflammatory cytokine expression. Both groups showed suppressed circadian regulators and whereas matrix changes in Group A were chondrogenic, in Group B they were non-chondrogenic with changes in mechanoreceptors, calcium signalling, ion channels and in cytoskeletal organisers. The gene expression changes predicted 478 potential biomarkers for detection in synovial fluid to distinguish patients from the two groups. Conclusions Two subgroups of knee OA were identified by network analysis of RNA-Seq data with evidence for the presence of two major pathogenic pathways. This has potential importance as a new basis for the stratification of patients with OA for drug trials and for the development of new targeted treatments.
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Authors: Courtney D. DiNardo, Caitlin R. Rausch, Christopher Benton, Tapan Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh R. Marx, Morgan Mace, Elias Jabbour, Jorge Cortes, Guillermo Garcia‐Manero, Farhad Ravandi, Kapil N. Bhalla, Hagop Kantarjian, Marina Konopleva
Journal: American Journal of Hematology (2017)

Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment-naïve elderly AML patients. VEN treatment combinations in R/R AML have not been previously reported.All R/R myeloid patients (including AML, myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN)) treated with VEN combinations in the salvage setting were reviewed.Forty-three patients with median age 68 (range, 25-83) were treated for AML (91%), MDS (5%), or BPDCN (5%). Most (n = 36, 84%) were ≥ salvage-2 treatment status, including prior hypomethylating agent (HMA) in 77%. In combination with VEN, most patients received HMA therapy (n = 31, 72%); eight (19%) received low-dose cytarabine (LDAC). Patients received a median of 2 treatment cycles (range, 1-4). Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia-free state (MLFS). Median survival was 3.0 months (range, 0.5-8.0), and estimated 6-month survival was 24%. Responses were observed in five (24%) of 21 patients with intermediate-risk cytogenetics, 3 (27%) of 11 IDH1/2-mutant, and 4 (50%) of 8 RUNX1-mutated patients. Two (20%) of 10 TP53-mutated patients responded; both had concurrent RUNX1 mutations. Of the 3 (15%) responding patients with adverse cytogenetics, all had concurrent RUNX1 mutations.Low-intensity chemotherapy, including HMAs or LDAC, in combination with VEN is a viable salvage option, even in multiply relapsed/refractory patients with AML, MDS, and BPDCN. Notable responses were identified in patients with diploid/intermediate cytogenetics, RUNX1, and/or IDH1/2 mutations.
Does the use of Local Anaesthetic (LA) Spray Combined With IV Sedation for Diagnostic OGD (Oesophagogastroduodenoscopy) Affect 8-Day Re-Admission and 30-Day Mortality?
Authors: N. Dilaver, J. Ansell, C. Brown, R. Egan, C. Leaman, S. Arunachalam, J. Williamson, J. Turner
Journal: International Journal of Surgery (2017)
HTLV-I infection is crippling
Authors: J A Copplestone, A G Prentice, M D Hamon, J Gawler, N Anderson
Journal: BMJ (1994)

ation ensures that roughly equal numbers move into arms 1 and 2 and also removes the possible bias introduced by the doctor choosing subsequent treatment.Patients are also less likely to be lost to follow up.Mortality figures will be analysed on an intention to treat basis.'We will also be able to compare survival in patients in arm 1 with that in the subgroup of patients in arm 3 who continue to take bromocriptine or are redrawn to arm 1; this will compare the benefits of starting with levodopa versus starting with bromocriptine.In addition, we can use data for patients redrawn from arm 3 to increase the power of analysis of survival in arms 1 and 2.
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study
Authors: Takashi Kawai, Kazunori Oda, Nobuo Funao, Akira Nishimura, Yasushi Matsumoto, Yuji Mizokami, Kiyoshi Ashida, Kentaro Sugano
Journal: Gut (2017)

Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study.Double-blind, randomised, non-inferiority study; single-blind extension study at 104 Japanese sites, including 621 patients (439 in extension) with a history of peptic ulcers who required long-term LDA therapy. Randomised (1:1:1, computer generated) patients received lansoprazole 15 mg (n=217), vonoprazan 10 mg (n=202) or vonoprazan 20 mg (n=202) once daily for 24 weeks (double blind) and ≤2 years (extension). The following measurements were made: 24-week (primary outcome; double blind) and 12-week peptic ulcer recurrence rate, 24-week GI bleeding rate, cumulative incidences of peptic ulcer recurrence and GI bleeding, treatment-emergent adverse events, laboratory results, serum gastrin and pepsinogen I/II concentrations.The 24-week peptic ulcer recurrence rate was 2.8%, 0.5% and 1.5% in the lansoprazole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, respectively. Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc analyses of the extension study, peptic ulcer recurrence rates were significantly lower with vonoprazan 10 mg (log-rank test, P=0.039), but not vonoprazan 20 mg (P=0.260), compared with lansoprazole 15 mg. GI bleeding rates were higher with lansoprazole compared with two doses of vonoprazan in both 24-week study and extension study.Vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA therapy, had a similar long-term safety profile and was well tolerated.NCT01452763; NCT01456247.
Informing vs Changing the Practice of Carotid Revascularization
Authors: James F. Meschia
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Patients’ willingness to defer resection of diminutive polyps: results of a multicenter survey
Authors: Daniel von Renteln, Mickael Bouin, Alan Barkun, Audrey Weber, Douglas Robertson, Joseph Anderson, Heiko Pohl
Journal: Endoscopy (2017)

Abstract Background and study aims Current colonoscopy practice requires removal of diminutive polyps. This is associated with costs, but the benefits to colorectal cancer (CRC) prevention remain unclear. The study aim was to understand patients’ willingness to defer resection of diminutive polyps and to examine the factors that influence patients’ decisions. Patients and methods Adults presenting for a colonoscopy were surveyed at three hospitals in the USA and Canada. Survey domains included: patient characteristics, risk perception, knowledge about CRC risk, willingness to defer polyp resection, and associated concerns. The primary endpoint was the proportion of patients who would be willing to participate in a clinical trial that deferred resection of diminutive polyps. Secondary endpoints included factors associated with willingness to defer diminutive polyp resection. Results 557 eligible individuals completed the survey (mean age 63; 61 % men), with 50 % of respondents being willing to participate in a randomized trial in which resection of diminutive polyps would be deferred until the next surveillance colonoscopy (95 % confidence interval [CI] 46 % – 55 %). Outside of a clinical trial, 57 % of participants would be agreeable to deferring resection of diminutive polyps (95 %CI 51 % – 63 %). Willingness to defer diminutive polyp resection was associated with higher education (P = 0.001), greater knowledge about cancer risk (P = 0.002), and a lower perception of cancer risk (all P &lt; 0.001). Age, sex, income, a history of polyps, and a first-degree family member with CRC were not associated with willingness to defer diminutive polyp resection. Conclusions More than half of individuals undergoing a routine colonoscopy would be agreeable to deferring resection of diminutive polyps and participating in a trial to evaluate this approach.
Successful endoscopic treatment of a “windsock” diverticulum: a rare case of duodenal subocclusion
Authors: Marco D’Assuncao, Lucas Nova da Costa, Fernando Mota, Saverio Armellini, Willian Igi, Juliana Valenciano, Amanda Ziegler
Journal: Endoscopy (2017)

Intraluminal “windsock” diverticulum is a rare congenital anomaly, caused by an incomplete recanalization of the duodenum during embryological development [1]. Although most cases are asymptomatic, patients may present with abdominal pain, postprandial fullness, and vomiting. The mean time of presentation is during the fourth decade of life. The most common complications are bleeding, partial bowel obstruction, and, rarely, pancreatitis [2]. Different treatment options have been described [3] [4] and, to our knowledge, fewer than 40 cases of endoscopic treatment have been reported to date.
Evolution du risque transfusionnel de transmission des infections virales (VIH, VHC, VHB) entre 1992 and 2003 en France et impact du test de dépistage génomique viral
Authors: J Pillonel, S Laperche
Journal: Eurosurveillance (2005)

La surveillance des tendances du risque residuel de transmission d’infections virales par transfusion sanguine est importante pour evaluer les ameliorations dans le domaine de la securite des produits sanguins et adapter les politiques de reduction des risques. Ces tendances ont ete etudiees en France sur quatre periodes de trois ans (1992-1994, 1995-1997, 1998-2000 et 2001-2003). Les estimations pour 2001-2003 ont ete comparees aux resultats du depistage genomique viral (DGV) pour le VIH-1 et le VHC realises, en juillet 2001, sur tous les dons de sang. 
Du fait de l’amelioration du recrutement et de la selection des donneurs, des progres en matiere de reactifs de depistage, et des mesures de prevention pour le controle des infections, les risques residuels pour le VIH, le VHC et le VHB ont connu une baisse tres importante entre 1992 et 2003. A l’heure actuelle, le risque residuel est extremement faible; entre 2001-2003, il etait estime a 1 pour 3,15 millions de dons pour le VIH, 1 pour 10 millions pour le VHC, et 1 pour 640 000 pour le VHB. Sur les 6,14 millions de dons analyses par DGV entre juillet 2001 et decembre 2003, deux dons positifs pour le VIH et 3 positifs pour le VHC ont pu etre elimines, soit un gain de 1 pour 3,07 millions pour le HIV et de 1 pour 2,05 millions pour le VHC. Ces resultats montrent aussi bien l’interet limite du DGV que son faible rapport cout-efficacite.
Abstract B28: Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men
Authors: Mark Preston, Travis Gerke, Sigrid V. Carlsson, Lisa Signorello, Daniel D. Sjoberg, Sarah C. Markt, Adam S. Kibel, Quoc-Dien Trinh, Mark Steinwandel, William Blot, Andrew J. Vickers, Hans Lilja, Lorelei A. Mucci, Kathryn M. Wilson
Journal: Cancer Research (2017)

Abstract Background: Baseline prostate specific antigen (PSA) levels measured in midlife predict future prostate cancer mortality among white men. There are minimal data on whether a baseline PSA in African-American men, who experience the highest incidence and mortality of this disease, predicts future aggressive prostate cancer. Methods: We undertook a nested case-control study among African-American men age 40 to 64 years who gave prediagnostic blood at enrollment in the Southern Community Cohort Study between 2002-2009 and were followed a median of 9 years for cancer incidence and mortality through 2015. Baseline total and free PSA levels were available for 197 prostate cancer cases (55 aggressive cases, Gleason ≥4+3=7, AJCC Stage III or IV, or cancer-specific death) and 569 age-matched controls. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between baseline PSA levels and risk of total and aggressive prostate cancer. Results: Median PSA among controls was 0.72, 0.80, 0.94, and 1.03 ng/mL for men aged 40 to 49, 50 to 54, 55 to 59, and 60 to 64 years, respectively. Relative risk of total prostate cancer was strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the &amp;gt;90th percentile vs. ≤median were 93.7 (22.5-390) at 40 to 54 years and 77.0 (24.9-238) at 55 to 64 years. Risk of aggressive prostate cancer was also strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the &amp;gt;90th percentile vs. ≤median were 80.8 (14.7 to infinity) at 40-54 years Citation Format: Mark Preston, Travis Gerke, Sigrid V. Carlsson, Lisa Signorello, Daniel D. Sjoberg, Sarah C. Markt, Adam S. Kibel, Quoc-Dien Trinh, Mark Steinwandel, William Blot, Andrew J. Vickers, Hans Lilja, Lorelei A. Mucci, Kathryn M. Wilson. Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr B28.
Impairment of membrane TNFα expression reduces cytotoxic activity of dendritic cells against autologous tumor cells in high-grade glioma patients
Authors: T. Tyrinova, O. Leplina, S. Mishinov, M. Tikhonova, A. Kalinovskiy, S. Chernov, V. Stupak, A. Ostanin, E. Chernykh
Journal: Annals of Oncology (2017)
Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex
Authors: Pharavee Jaiprasart, Bertrand Z. Yeung, Ze Lu, M. Guillaume Wientjes, Minjian Cui, Chien-Ming Hsieh, Sukyung Woo, Jessie L.-S. Au
Journal: Journal of Controlled Release (2017)
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial
Authors: Jean-Michel Molina, Isabelle Charreau, Christian Chidiac, Gilles Pialoux, Eric Cua, Constance Delaugerre, Catherine Capitant, Daniela Rojas-Castro, Julien Fonsart, Béatrice Bercot, Cécile Bébéar, Laurent Cotte, Olivier Robineau, François Raffi, Pierre Charbonneau, Alexandre Aslan, Julie Chas, Laurence Niedbalski, Bruno Spire, Luis Sagaon-Teyssier, Diane Carette, Soizic Le Mestre, Veronique Doré, Laurence Meyer, C. Pintado, B. Loze, C. Gatey, D. Ponscarme, P. Penot, R. Veron, J. Delgado, E. Dalle, S. Parlier, I. Madelaine, M. Danet, N. Mahjoub, N. Mezreb, K. Moudachirou, S. Morel, G. Conort, F. Lorho, M. Meunier, W. Rozenbaum, C. Monfort, J. Foucoin, B. Boissavy, S. Cousseau, S. Huon, M. Danet, A. Djessima, V. Berrebi, A. Adda, S. le Nagat, L. Zarka, J. Berdougo, N. Mzoughi, F. Clement, A. Decouty, C. Chapolard, M. Godinot, C. Adouard-groslafeige, J. Koffi, A. Pansu, A. Becker, S. Pailhes, F. Bonnet, F. Jeanblanc, C. Brochier, X. Teruin, S. Rouby, L. Gilly, C. Etienne, F. Tolonin, S. Breaud, V. Péchenot, S. Bagge, T. Cepitelli, PM. Roger, E. Rosenthal, A. Cheret, P. Cornavin, S. Vandamme, J. Lambec, N. Dumon, O. Leclanche, T. Huleux, R. Biekre, H. Melliez, H. Bazus, A. Pasquet, C. Bernaud, M. Besnier, B. Bonnet, N. Hall, M. Cavellec, H. Hue, L. Larmet, M. Colas, R. Choquet, S Fouéré, E. Netzer, N. Leturque, J. Binesse, V. Foubert, M. Saouzanet, F. Euphrasie, B. Guillon, Y. Saïdi, M. Suzan, G. Cattin, B. Demoulin, N. Lorente
Journal: The Lancet Infectious Diseases (2017)
Chronic pain in pachyonychia congenita: evidence for neuropathic origin
Authors: S. Brill, E. Sprecher, F.J.D. Smith, N. Geva, H. Gruener, H. Nahman-Averbuch, R. Defrin
Journal: British Journal of Dermatology (2017)

Pachyonychia congenita (PC) is a rare autosomal dominant skin disease, with chronic pain being the most prominent complaint. Histological studies showing alterations in sensory innervation, along with reports on alterations in mechanical sensitivity, suggest that PC may be a form of neuropathy. Here, for the first time, we aim to evaluate systematically the sensory function of patients with PC vs. controls, in order to investigate the pathophysiology of PC. Patients (n = 62) and controls (n = 45) completed the McGill and Douleur Neuropathique‐4 (DN4) questionnaires. Sensory testing included detection and pain thresholds, pathological sensations, conditioned pain modulation (CPM) and temporal summation of pain. A moderate‐to‐severe chronic pain in the feet, throbbing and stabbing in quality, was highly prevalent among patients with PC (86%) and was especially debilitating during weight bearing. In addition, the majority of patients had a DN4 score ≥ 4 (62%), static allodynia (55%) and tingling (53%) in the feet. Compared with controls, patients with PC exhibited thermal and mechanical hypoaesthesia and mechanical hyperalgesia in the feet. CPM was reduced among the patients, and was associated with more enhanced mechanical hyperalgesia in the feet. The specific gene and nature of the causative mutation did not affect any of these features. Although thermal and mechanical hypoaesthesia may result from thicker skin, its presentation in painful regions, along with mechanical hyperalgesia and allodynia, point towards the possibility of neuropathic changes occurring in PC. The clinical features and DN4 scores support this possibility and therefore neuropathic pain medications may be beneficial for patients with PC.
IMA950 multipeptide vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients
Authors: V. Dutoit, D. Migliorini, A. Patrikidou, A. Mayer-Mokler, N. Hilf, P.R. Walker, P-Y Dietrich
Journal: Annals of Oncology (2017)
Reducing the Underimmunization of Transplant Recipients
Authors: Amy G. Feldman, Chris Feudtner, Allison Kempe
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies
Authors: Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein
Journal: The Lancet Diabetes & Endocrinology (2017)